Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) decided at a board meeting held on June 24 to integrate its active pharmaceutical ingredient (API)...
Read more about Separation of the API Production at Takahagi Site
Japan, June 10, 2005 - Astellas Pharma Inc. ("Astellas") today announced that a new dosage form of Harnal® (generic name: tamsulosin HCl), the orally disintegrating tablet "Harnal® D Tablet...
Deerfield, Ill., May 26, 2005- King Pharmaceuticals Research and Development, Inc. ("King") along with Astellas US LLC and Astellas Pharma US, Inc. ("Astellas") announced today that they have...
Japan, May 17, 2005 - Astellas Pharmaceutical Co., Ltd.(Astellas) today announced that Astellas has decided a dissolution of Astellas Medical Care Co., Ltd., its wholly owned subsidiary engaged in...
Read more about Astellas will Dissolve its Subsidiary for Home Care business
Follow us
